Company Information
Teva Generics Company Intelligence Report
Company Intelligence Report
| Publication Date | March 2009 |
| Publisher | Espicom |
| Product Type | Report |
| Pages | 46 |
| ISBN Number | not applicable |
| Product Code | ESP00394 |
Price
£195.00
approximately: $320 | €227
approximately: $320 | €227
Order above formats by FAX
Summary
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Contents
- Executive Summary
- Introduction
- Products
- Summary of Teva's presence in Europe
- Antares/Teva file sNDA for needlefree injector for HGH product
- Teva ANDA Approvals 2002-09
- IVAX ANDA Approvals, 2002-08
- Gensia Sicor Pharmaceuticals / Sicor ANDA Approvals, 2003-07
- Pharmachemie ANDA Approvals, 2003-07
- Novopharm ANDA Approvals, 2002-04
- Goldline Laboratories / Zenith Goldline ANDA Approvals, 2002-05
- Recent product approvals
- Mixed amphetamine salts
- Drospirenone / ethinyloestradiol
- Topiramate
- Minocycline
- CHMP adopts positive opinions on Rivastigmine Teva
- Sumatriptan
- Risperidone
- Levetiracetam
- Teva gains tentative quetiapine approval
- Teva gains budesonide approval
- Teva launches its fentanyl transdermal system
- CHMP adopts positive opinion for Pramipexole Teva
- Teva's ProAir HFA gains new paediatric respiratory indication
- Teva gains EMEA approvals for filgrastim products
- Nicardipine (US)
- Lamotrigine (US)
- Teva receives FDA approval for generic Risperdal Tablets
- Valsartan (IVAX, tentative)
- Teva begins shipping bupropion tablets
- Teva gains FDA approval of generic Sarafem Pulvules
- Epoprostenol
- Rizatriptan (tentative)
- Raloxifene (tentative)
- Irinotecan hydrochloride
- Alendronate
- TEVA GENERIC COMPANIES ANALYSIS
- Tamsulosin (tentative)
- Lansoprazole (tentative)
- Pravastatin
- Sumatriptan (UK)
- Ceftriaxone
- Donepezil
- Financial results
- Latest Quarterly Results, Q4 2008
- Teva Pharmaceutical Industries: fourth quarter results, in US$ millions
- Teva Pharmaceutical Industries: fourth quarter results in detail, in US$ millions
- Latest Fiscal Year Results, 2008
- Full Year Results, 2003 - 2008 (US$ millions)
- Pharmaceutical Sales
- North America
- Europe
- International
- Innovative Products
- Biogenerics
- Major developments
- FDA declines to review Teva Citizen Petition
- Teva reports success in AOK tenders in the German market
- Mergers, acquisitions and agreements
- Dynamix enters drug-discovery/development alliance with Teva
- Teva and Lonza announce strategic partnership
- Jexys enters R&D collaboration with Teva
- Indevus/Teva enter deal to develop pagoclone for stuttering
- Teva acquires Barr
- Teva and Kowa form strategic partnership to concentrate on Japanese generic market
- Teva and Proteologics extend anticancer collaboration
- Consortium acquires Teva's controlling stake in IVAX Diagnostics
- Teva to market CEL-SCI's Multikine in Israel and Turkey
- Teva signs agreement for Capricorn's Korkoat technology platform
- Teva acquires Bentley Pharmaceuticals
- Czech expansion
- Irish expansion
- Hungarian expansion
- CoGenesys acquisition
- UCB
- Litigation
- Cubist files patent lawsuit against Teva
- GENERIC COMPANIES ANALYSIS TEVA
- OSI files lawsuits against Teva and Mylan
- Sepracor settles levalbuterol litigation against Teva / Barr
- Eli Lilly gains raloxifene temporary restraining order
- Gilead files emtricitabine patent infringement lawsuit against Teva
- Teva loses lansoprazole litigation
- California court rules branded firms can be liable for generics
- sanofi-aventis settles Nasacort AQ and certain Allegra/Allegra D-12 US patent litigations
- Teva gains budesonide approval, flurry of activity results
- Appellate court reverses generic risperidone exclusivity decision
- Teva and Dr Reddy's settle carvedilol suit
- Appeals Court favours Eisai in rabeprazole judgement
- Summary judgement granted for Seroquel patent litigation
- Enoxaparin
- Escitalopram (UK)
- Brussels court revokes MSD's European alendronate patent
- Depomed enters deal to settle patent litigation against IVAX
- Quetiapine
- Celecoxib
- Solvay subsidiaries file fenofibrate suits against Teva
- Forest and Merz file lawsuits for memantine patent infringement
- Contact Details
